tetano
Editor, Senior Moderator
Clin Chem Lab Med. 2020 May 14. pii: /j/cclm.ahead-of-print/cclm-2020-0502/cclm-2020-0502.xml. doi: 10.1515/cclm-2020-0502. [Epub ahead of print]
COVID-19: progression of disease and intravascular coagulation - present status and future perspectives.
Harenberg J[SUP]1[/SUP], Favaloro E[SUP]2[/SUP].
Author information
Abstract
The timely and accurate diagnosis of infection with severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), remains the cornerstone of efforts to provide appropriated treatment for patients, to limit further spread of the virus and ultimately to eliminate the virus from the human society. We focus this article on (a) developments for improvement of diagnosis of specific SARS-CoV-2 virus, (b) laboratory changes in the immunologic and coagulation system, (c) therapeutic options for anticoagulant treatment of seriously affected patients and (d) on the perspectives through improvement of diagnostic and therapeutic medical procedures.
KEYWORDS:
COVID-19; D-dimer; SARS-CoV-2; antibodies; anticoagulation; autopsy; coagulation parameters; disseminated intravascular coagulation; heparin; low-molecular-weight heparin; pulmonary embolism; thrombosis
PMID:32406381DOI:10.1515/cclm-2020-0502
COVID-19: progression of disease and intravascular coagulation - present status and future perspectives.
Harenberg J[SUP]1[/SUP], Favaloro E[SUP]2[/SUP].
Author information
Abstract
The timely and accurate diagnosis of infection with severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), remains the cornerstone of efforts to provide appropriated treatment for patients, to limit further spread of the virus and ultimately to eliminate the virus from the human society. We focus this article on (a) developments for improvement of diagnosis of specific SARS-CoV-2 virus, (b) laboratory changes in the immunologic and coagulation system, (c) therapeutic options for anticoagulant treatment of seriously affected patients and (d) on the perspectives through improvement of diagnostic and therapeutic medical procedures.
KEYWORDS:
COVID-19; D-dimer; SARS-CoV-2; antibodies; anticoagulation; autopsy; coagulation parameters; disseminated intravascular coagulation; heparin; low-molecular-weight heparin; pulmonary embolism; thrombosis
PMID:32406381DOI:10.1515/cclm-2020-0502